Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma

被引：6

作者：

Maruyama, Dai ^{[1
]}

Nagai, Hirokazu ^{[2
]}

Fukuhara, Noriko ^{[3
]}

Kitano, Toshiyuki ^{[4
]}

Ishikawa, Takayuki ^{[5
]}

Nishikawa, Tomoaki ^{[6
]}

机构：

[1] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[2] Natl Hosp Org Nagoya Med Ctr, Dept Hematol, Nagoya, Aichi, Japan

[3] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan

[4] Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Kyoto, Japan

[5] Kobe City Med Ctr Gen Hosp, Dept Hematol, Kobe, Hyogo, Japan

[6] Janssen Pharmaceut KK, Tokyo, Japan

来源：

关键词：

covalent BTK inhibitor; ibrutinib; Japanese patients; mantle cell lymphoma; phase II clinical trial;

D O I：

10.3960/jslrt.19006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：98 / 100

页数：3